reversal

Resorcinolnaphthalein is a specific enhancer of angiotensin-converting enzyme 2 (ACE2) (EC50 value of 19.5 μM).

Sugammadex sodium (Org25969) , a synthetic derivative of γ-cyclodextrin, is a steroid-based neuromuscular blocker reversing agent.

Heparin reversal agent-1 (Compound QA-1) acts as a neutralizing agent for Heparin. It effectively reverses the anticoagulant activity of unfractionated heparin and low molecular weight heparins, including Dalte, Enoxa, and Nadro.

Rubone (2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone), a natural product and a modulator of miR-34a (microRNA-34), upregulates miR-34a expression in a p53-dependent manner, which in turn downregulates the expression of downstream targets Bcl-2, cyclin-D1, CDK6, SIRT1, and FOXP1, thereby inhibiting tumor growth and reversal of hepatocellular carcinoma (HCC) and chemoresistance in prostate cancer.

1-Methyladenine is a DNA alkylation product that undergoes damage reversal through oxidative demethylation for repair purposes.

Ciraparantag is an inhibitor of thrombin and factor Xa. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including unfractionated heparin, low-molecular-weight heparin, and certain direct oral anticoagulants.

Ciraparantag TFA is an inhibitor of thrombin and factor Xa. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including unfractionated heparin, low-molecular-weight heparin, and certain direct oral anticoagulants.

Ciraparantag acetate, an anticoagulant reversal agent, is a small molecule specifically designed to bind noncovalently by charge-charge interaction to unfractionated heparin and low-molecular-weight heparin. It shows binding characteristics that are similar to those of direct oral anticoagulants (DOACs).

ABCB1-IN-2 (compound 16q) is a functional inhibitor that directly binds and stabilizes the ABCB1 protein structure without altering its expression and subcellular localization. This compound enhances the sensitivity of MCF-7/ADR cells to paclitaxel (PTX) by increasing PTX accumulation and inhibiting the ABCB1-mediated accumulation and excretion of luciferin Rh123. As a potent ABCB1-mediated multidrug resistance (MDR) reversal agent, ABCB1-IN-2 effectively reverses MDR.

DOCP (2-((2,3-Bis(oleoyloxy)propyl)dimethylammonio)ethyl hydrogen phosphate) is a lipid characterized by an opposite charge orientation compared to traditional phosphatidylcholine (PC) lipids, featuring quaternary ammonium near the bilayer interface and phosphate groups projecting into the aqueous environment. This unique structure of iPC lipids presents an excellent opportunity to investigate the biophysical characteristics and biological activities influenced by the reversal of surface charges on bilayers.

Prenoverine is a diphenylmethanol derivative with effective multidrug resistance reversal activity.

P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). This compound demonstrates multidrug resistance (MDR) reversal activity in cancer, with an IC50 for Paclitaxel of 8.80 and a reversal fold of 211.8.

ATB-429 is a mesalazine derivative capable of releasing H2S, demonstrating significant analgesic and anti-inflammatory effects in an irritable bowel syndrome (IBS) model. By releasing hydrogen sulfide (H2S), ATB-429 modulates hypersensitivity induced by colorectal distension in healthy and post-colitis rats. It alleviates abdominal withdrawal responses and inhibits spinal c-Fos mRNA expression, indicating its potential to relieve pain associated with gastrointestinal inflammation. Furthermore, ATB-429 downregulates mRNA expression of colonic cyclooxygenase-2 (COX-2) and IL-1β, an effect not observed with mesalazine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, evidenced by the reversal of ATB-429's effects with glibenclamide. These findings suggest that ATB-429 may offer therapeutic benefits for treating inflammatory pain-related bowel conditions.

Hydrocinchonine is reported to have multidrug resistance reversal activity, which can weaken drug resistance by inhibiting the function of P-gp and possibly affecting its expression. In MES-SA/DX5 cells, the combination of Hydrocinchonine and Paclitaxel can enhance the apoptosis.

P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor with low cytotoxicity, demonstrating significant multidrug resistance (MDR) reversal activity against doxorubicin in MCF7/ADR cells. It has an IC50 value of 0.11 μM and a resistance reversal factor (RF) of 215.9. P-gp-IN-32 interacts directly with P-gp, inducing conformational changes and inhibiting its efflux function. This compound is applicable in cancer research, including studies on breast cancer.

Tubulin polymerization/P-gp-IN-1 is a dual inhibitor targeting both tubulin polymerization and P-gp. It disrupts tubulin polymerization, inducing G2/M phase arrest and apoptosis (apoptosis). By inhibiting P-gp's efflux function, it reverses multidrug resistance (MDR). Tubulin polymerization/P-gp-IN-1 has dual roles: direct antitumor activity and reversal of P-gp-mediated cisplatin resistance. It binds stably to the tubulin CBS domain (ΔG = −12.4 kcal/mol) and the P-gp hydrophobic cavity (ΔG = −10.8 kcal/mol). Tubulin polymerization/P-gp-IN-1 is applicable for research on drug-resistant cervical cancer.

Acerinol is an active ingredient from traditional Chinese medicinal herbs. It could be used as a cancer multidrug resistance reversal agent. Acerinol can significantly stimulate the activity of ABCB1 ATPase without affecting the expression of ABCB1 on nei

trans-Trimethoxyresveratrol (MR-3), a natural methoxylated analog of resveratrol, inhibits breast Y cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

Simetride is used in the Reversal of resistance to vincristine in P388 leukemia.

Deacetylforskolin is a diterpene and a derivative of forskolin that has been found inC. forskohliiand has diverse biological activities.1,2,3,4It activates rat adipocyte adenylyl cyclase (IC50= 20 μM) and inhibits glucose transport in rat adipocyte plasma membranes.2Deactylforskolin (30-1,000 μg/kg) reduces blood pressure in spontaneously hypertensive rats.3It also attenuates hypercapnia-induced impairments in the passive avoidance response in mice.4 1.Gabetta, B., Zini, G., and Danieli, B.Minor Diterpenoids of Coleus forskohliiPhytochemistry28(3)859-862(1989) 2.Joost, H.G., Habberfield, A.D., Simpson, I.A., et al.Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: structural determinants for distinct sites of actionMol. Pharmacol.33(4)449-453(1988) 3.Bhat, S.V., Dohadwalla, A.N., Bajwa, B.S., et al.The antihypertensive and positive inotropic diterpene forskolin: Effects of structural modifications on its activityJ. Med. Chem.26(4)486-492(1983) 4.McCulloch, A.J., Thomson, T.A., and Deacon, R.Hypoxic amnesia and its reversal with forskolinBiochem. Soc. Trans.17(1)212-213(1988)

Astragaloside II (Astrasieversianin VIII) is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

1. Tectochrysin (Techtochrysine) has antioxidant effect. 2. Tectochrysin is promising inhibitors for the reversal of ABCG2-mediated drug transport. 3. Tectochrysin leads to apoptotic cell death in NSC-LC cells through activation of DR3 and Fas expression via inhibition of STAT3 phosphorylation.

Cinobufotalin is a main cardiac toxin in toad, it is a novel anti-HCC agent, it induces growth inhibition and apoptosis in cultured HCC cells through ceramide production. Cinobufotalin is also an effective reversal agent for the multidrug resistance of tu

1. Pristimerin (Celastrol methyl ester) has anticancer activity , treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells. 2. Pristimerin down-regulates the expression of pro-inflammatory mediators through blocking of NF-κB activation by inhibiting interconnected ROS/IKK/NF-κB signaling pathways, can effectively inhibit both arthritic inflammation and cartilage and bone damage in the joints.